The Journal of Clinical Psychiatry

Page 159

More JCP Articles

Commentary

Do Antipsychotics Cause Hip Fractures? Promise and Pitfalls of Big Data

September 23, 2015

John M. Davis , Christopher E. Ramsden

Original Research

Antipsychotic Treatment and the Risk of Hip Fracture in Subjects With Schizophrenia: A 10-Year Population-Based Case-Control Study

September 23, 2015

Chi-Shin Wu , Chia-Ming Chang , Yu-Ting Tsai , et al

Clinical and Practical Psychopharmacology

Bioequivalence of Generic Drugs

September 23, 2015

Chittaranjan Andrade

Original Research

Clinical Staging of Major Depressive Disorder: An Empirical Exploration

September 23, 2015

Judith Verduijn , Yuri Milaneschi , Albert M. van Hemert , et al

Book Review

Clinician’s Guide to Bipolar Disorder: Integrating Pharmacology and Psychotherapy

September 23, 2015

Scott R. Turkin

Book Review

Cocaine and Methamphetamine Dependence: Advances in Treatment

September 23, 2015

Matthew E. Layton

Original Research

Current and Remitted Depression and Anxiety Disorders as Risk Factors for Medication Nonadherence

September 23, 2015

Pierre M. Bet , Brenda W. J. H. Penninx , Stag D. van Laer , et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Michael E. Thase , James M. Youakim , Aleksandar Skuban , et al

Commentary

Electroconvulsive Therapy for Bipolar Disorder: Evidence Supporting What Clinicians Have Long Known

September 23, 2015

Charles H. Kellner , Gabriella M. Ahle , Emma T. Geduldig

Commentary

Electroconvulsive Therapy in Bipolar Mixed States: An Overlooked Option

September 23, 2015

Andrea Murru

Original Research

Electroconvulsive Therapy in 197 Patients With a Severe, Drug-Resistant Bipolar Mixed State: Treatment Outcome and Predictors of Response

September 23, 2015

Pierpaolo Medda , Cristina Toni , Michela Giorgi Mariani , et al

Letter to the Editor

US Food and Drug Administration Warning About the Risk of Drug Reaction with Eosinophilia and Systemic Symptoms With Ziprasidone

September 23, 2015

Vicky C. Chan , Lois La Grenade , Ida-Lina Diak , et al

« 1 … 157 158 159 160 161 … 757 »

Do Antipsychotics Cause Hip Fractures? Promise and Pitfalls of Big Data

Antipsychotic Treatment and the Risk of Hip Fracture in Subjects With Schizophrenia: A 10-Year Population-Based Case-Control Study

Bioequivalence of Generic Drugs

Clinical Staging of Major Depressive Disorder: An Empirical Exploration

Clinician’s Guide to Bipolar Disorder: Integrating Pharmacology and Psychotherapy

Cocaine and Methamphetamine Dependence: Advances in Treatment

Current and Remitted Depression and Anxiety Disorders as Risk Factors for Medication Nonadherence

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Electroconvulsive Therapy for Bipolar Disorder: Evidence Supporting What Clinicians Have Long Known

Electroconvulsive Therapy in Bipolar Mixed States: An Overlooked Option

Electroconvulsive Therapy in 197 Patients With a Severe, Drug-Resistant Bipolar Mixed State: Treatment Outcome and Predictors of Response

US Food and Drug Administration Warning About the Risk of Drug Reaction with Eosinophilia and Systemic Symptoms With Ziprasidone

ELSEWHERE:

FOLLOW US:

More JCP Articles

Do Antipsychotics Cause Hip Fractures? Promise and Pitfalls of Big Data

Antipsychotic Treatment and the Risk of Hip Fracture in Subjects With Schizophrenia: A 10-Year Population-Based Case-Control Study

Bioequivalence of Generic Drugs

Clinical Staging of Major Depressive Disorder: An Empirical Exploration

Clinician’s Guide to Bipolar Disorder: Integrating Pharmacology and Psychotherapy

Cocaine and Methamphetamine Dependence: Advances in Treatment

Current and Remitted Depression and Anxiety Disorders as Risk Factors for Medication Nonadherence

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Electroconvulsive Therapy for Bipolar Disorder: Evidence Supporting What Clinicians Have Long Known

Electroconvulsive Therapy in Bipolar Mixed States: An Overlooked Option

Electroconvulsive Therapy in 197 Patients With a Severe, Drug-Resistant Bipolar Mixed State: Treatment Outcome and Predictors of Response

US Food and Drug Administration Warning About the Risk of Drug Reaction with Eosinophilia and Systemic Symptoms With Ziprasidone

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles